COMMUNIQUÉS West-GlobeNewswire
-
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
09/04/2026 -
Seres Therapeutics to Present at CARB-X Investor Day
09/04/2026 -
Nkarta to Participate in Needham Virtual Healthcare Conference
09/04/2026 -
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
09/04/2026 -
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
09/04/2026 -
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
09/04/2026 -
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
09/04/2026 -
Losing Your Voice? Millions Experience Persistent Problems Each Year
09/04/2026 -
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09/04/2026 -
Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
09/04/2026 -
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
09/04/2026 -
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026 -
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026 -
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09/04/2026 -
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
09/04/2026 -
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
09/04/2026 -
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
09/04/2026 -
New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research
09/04/2026 -
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
09/04/2026
Pages